CALGARY, March 15, 2017 /PRNewswire/ - Resverlogix Corp.
("Resverlogix" or the "Company") (TSX: RVX) today announced the
receipt of a Notice of Allowance from the United States Patent and
Trademark Office (USPTO) for patent claims covering the use of
apabetalone in combination with Rosuvastatin in the United States. Rosuvastatin was
exclusively marketed by AstraZeneca under the trade name
Crestor® until its patent expired in 2016. The allowed
patent is entitled: "Compositions and Therapeutic Methods for
Accelerated Plaque Regression," and covers claims for both a single
composition as well as separate compositions of the two
drugs. Resverlogix has similar claims pending in other
jurisdictions.
"We are very pleased with the allowance of one of the key
patents, covering the combination of apabetalone with one of the
most successful statins on the market. It further solidifies
Resverlogix as a key player in the cardiovascular disease market,"
stated Donald McCaffrey, President
& Chief Executive Officer.
Mr. McCaffrey further stated, "Resverlogix devotes significant
resources to ensure the protection of ideas and inventions related
to the core areas of our business. We believe that our know-how in
multiple disease areas will provide a significant competitive
advantage. We intend to continue to develop and protect our
proprietary tools, methods, and trade secrets."
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a
first-in-class, small molecule that is a selective BET (bromodomain
and extra-terminal) inhibitor. BET bromodomain inhibition is an
epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the
second bromodomain (BD2) within the BET protein called BRD4. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with diseases such as high-risk cardiovascular disease
(CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's
disease, Orphan diseases, and peripheral artery disease, while
maintaining a well described safety profile. Apabetalone is the
only selective BET bromodomain inhibitor in human clinical trials,
currently in a Phase 3 trial BETonMACE in high-risk CVD patients
with type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX: RVX).
Follow us on Twitter:
@Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on
our blog at http://www.resverlogix.com/blog
This news release may contain certain forward-looking
information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
In particular, this news release includes forward looking
information relating to the Company's intellectual property and
patent claims covering the use of apabetalone in combination with
Rosuvastatin, Phase 2 Renal Impairment trial
and Phase 3 clinical trial, and the potential role of
apabetalone in the treatment of CVD, DM, chronic kidney disease,
Alzheimer's disease, Orphan diseases, and peripheral artery
disease. Our actual results, events or developments could be
materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of
the events or expectations will occur or be realized. By their
nature, forward-looking statements are subject to numerous
assumptions and risk factors including those discussed in our
Annual Information Form and most recent MD&A which are
incorporated herein by reference and are available through SEDAR
at www.sedar.com. The forward-looking statements
contained in this news release are expressly qualified by this
cautionary statement and are made as of the date hereof. The
Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
SOURCE Resverlogix Corp.